Immuno-Oncology | Specialty

The Biology of Prostate Cancer

July 31st 2017

FDA Grants Durvalumab Breakthrough Designation for NSCLC

July 31st 2017

The FDA has granted durvalumab a breakthrough therapy designation to treat patients with locally-advanced, unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation.

Dr. Stein Discusses Skin-Related AEs With Melanoma Treatment

July 28th 2017

Jennifer A. Stein, MD, PhD, an associate professor of dermatology at New York University School of Medicine in New York, discusses the skin-related adverse events (AEs) associated with melanoma treatment.

Therapeutic Options Developing for Non-Driver NSCLC, But Challenges Remain

July 27th 2017

Corey Langer, MD, discusses KEYNOTE-189, the current arena in NSCLC treatment, and the obstacles that remain in effectively treating patients with non-driver mutations.

Frontline Durvalumab Plus Tremelimumab Falls Short in Phase III NSCLC Trial

July 27th 2017

Frontline durvalumab (Imfinzi) did not improve progression-free survival in patients with stage IV metastatic non–small cell lung cancer compared with standard platinum-based chemotherapy.

Dr. Pavlick on Adjuvant Immunotherapy in High-risk Melanoma

July 27th 2017

Anna C. Pavlick, DO, associate professor of hematology and medical oncology and medical director of the Clinical Trials Office at the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the need for adjuvant immunotherapy in patients with high-risk melanoma.

Dr. Atkins on Excitement With Atezolizumab and Bevacizumab in RCC

July 27th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the excitement surrounding the combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma (RCC).

Dr. Plimack on Combo of Pembrolizumab/Epacodostat in Bladder Cancer

July 27th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the phase Ib trial of epacodostat and pembrolizumab (Keytruda) in patients with urothelial carcinoma.

Diverse Approaches Needed to Further Advance Bladder Cancer Care

July 27th 2017

Elizabeth Plimack, MD, recaps recent advances in bladder cancer and discusses the need for diverse approaches to further improve patient outcomes.

Apolo Talks Progress, Future of Immunotherapy in Bladder Cancer

July 26th 2017

Andrea Apolo, MD, discusses a pooled analysis of the phase Ib Javelin Solid Tumor study, and a phase I study of cabozantinib, nivolumab, and ipilimumab.

FDA Accepts sBLAs for 4-week Nivolumab Dosing Schedule

July 26th 2017

The FDA has accepted supplemental Biologics License Applications seeking to add a second dosing schedule for nivolumab (Opdivo) across all of the PD-1 inhibitor’s monotherapy indications.

Dr. Choueiri on Synergy Between Immunotherapy and VEGF Inhibitors in RCC

July 26th 2017

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the synergy between immunotherapy agents and VEGF inhibitors in renal cell carcinoma (RCC).

Dr. Garcia on Selecting Second-line Immunotherapy in Bladder Cancer

July 26th 2017

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses selecting a second-line and beyond immunotherapy treatment for patients with bladder cancer.

Rini Discusses Pembrolizumab/Axitinib, Other Emerging Combos in RCC

July 26th 2017

Brian Rini, MD, discusses the KEYNOTE-426 study and the promise of emerging combinations in renal cell carcinoma.

Dr. Bauml on Next Steps for Immunotherapy in Head and Neck Cancer

July 25th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the next steps for immunotherapy in head and neck cancer.

Expert Discusses Pembrolizumab Plus Rituximab in Follicular Lymphoma

July 25th 2017

Loretta Nastoupil, MD, discusses the positive interim analysis and shared her thoughts on areas of future investigation for patients with relapsed follicular lymphoma.

FDA Approves Ipilimumab for Pediatric Melanoma

July 24th 2017

The FDA has approved ipilimumab for the treatment of patients aged ≥12 years with unresectable or metastatic melanoma.

Atezolizumab Approaches EU Approval for NSCLC, Urothelial Carcinoma

July 22nd 2017

The European Medicines Agency’s Committee for Medicinal Products for Human Use has taken a positive position on indications for atezolizumab in non­-small cell lung cancer and urothelial carcinoma.

Dr. Balar on Combinations with Pembrolizumab for Urothelial Cancer

July 21st 2017

Arjun V. Balar, MD, assistant professor of Medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

Dr. Sartor on Remaining Questions With Sipuleucel-T in mCRPC

July 21st 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the remaining questions with sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer.